Zobrazeno 1 - 10
of 142
pro vyhledávání: '"Kostas, Kalbakis"'
Autor:
Stefania Kokkali, Emmanouil Saloustros, Dimitra Stefanou, Paris Makrantonakis, Nikolaos Kentepozidis, Ioannis Boukovinas, Nikolaos Xenidis, Panagiotis Katsaounis, Alexandros Ardavanis, Nikolaos Ziras, Athina Christopoulou, George Rigas, Kostas Kalbakis, Nikolaos Vardakis, Christos Emmanouilides, Ilias Athanasiadis, Athanassios Anagnostopoulos, Dora Hatzidaki, Efthimios Prinarakis, Foteini Simopoulou, Athanasios Kotsakis, Vassilis Georgoulias
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 1237-1251 (2022)
Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical records of mBC patients, treated with front-line BEV-based chemotherapy, were retrospectively re
Externí odkaz:
https://doaj.org/article/c982903354104203bb48bb3d0972f59f
Autor:
Alexios Matikas, Athanasios Kotsakis, Stella Apostolaki, Helen Politaki, Maria Perraki, Kostas Kalbakis, Michalis Nikolaou, Panagiota Economopoulou, Dora Hatzidaki, Vassilis Georgoulias
Publikováno v:
British Journal of Cancer. 126:1563-1569
BackgroundThe detection of circulating tumour cells (CTC) is prognostic for disease recurrence in early breast cancer (BC). This study aims to investigate whether this prognostic effect persists or varies over time.MethodsThe study population consist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6816b9ff29661e1659e8228a82037e1e
https://doi.org/10.1038/s41416-022-01699-5
https://doi.org/10.1038/s41416-022-01699-5
Autor:
Maria Papadaki, Dimitrios Mavroudis, Sofia Agelaki, Kostas Kalbakis, Eleni Lagoudaki, Alexia Monastirioti, Konstantina Thomopoulou, Chara Papadaki, Anastasios Koutsopoulos
Publikováno v:
Cancer Research. 80:P3-05
Background PD-L1 expression on tumor and immune cells plays an important role in many cancers, including breast cancer (BC), however, discordance has been demonstrated between primary tumors and matched distant metastases. PD-L1 is expressed on circu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b7392b18e9a5cbfe39f3302b7b86ddc
https://doi.org/10.1158/1538-7445.sabcs19-p3-05-03
https://doi.org/10.1158/1538-7445.sabcs19-p3-05-03
Autor:
Stefania Kokkali, Emmanouil Saloustros, Dimitra Stefanou, Paris Makrantonakis, Nikolaos Kentepozidis, Ioannis Boukovinas, Nikolaos Xenidis, Panagiotis Katsaounis, Alexandros Ardavanis, Nikolaos Ziras, Athina Christopoulou, George Rigas, Kostas Kalbakis, Nikolaos Vardakis, Christos Emmanouilides, Ilias Athanasiadis, Athanassios Anagnostopoulos, Dora Hatzidaki, Efthimios Prinarakis, Foteini Simopoulou, Athanasios Kotsakis, Vassilis Georgoulias
Publikováno v:
Current Oncology; Volume 29; Issue 2; Pages: 1237-1251
Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical records of mBC patients, treated with front-line BEV-based chemotherapy, were retrospectively re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d912d22acc3a1f5d3ceb8791b527d9c
https://pubmed.ncbi.nlm.nih.gov/35200604
https://pubmed.ncbi.nlm.nih.gov/35200604
Autor:
Sofia Agelaki, Antonia Kalykaki, Harris Markomanolaki, Maria A Papadaki, Galatea Kallergi, Dora Hatzidaki, Kostas Kalbakis, Dimitrios Mavroudis, Vassilis Georgoulias
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0123683 (2015)
To evaluate the efficacy of lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, in therapy-resistant HER2-positive CTCs in metastatic breast cancer (MBC).Patients with MBC and HER2-positive CTCs despite disease stabilization or response to pri
Externí odkaz:
https://doaj.org/article/cd3e9bf174ff4b51adb459ccbc06d601
Autor:
Diamantis P. Kofteridis, Antonios Valachis, Eirini Koutsounaki, Sofia Maraki, Eleni Mavrogeni, Foteini N. Economidou, Dimitra Dimopoulou, Kostas Kalbakis, Vassilis Georgoulias, George Samonis
Publikováno v:
The Scientific World Journal, Vol 2012 (2012)
Background. Skin and soft tissue infections (SSTIs) in cancer patients represent a diagnostic challenge, as etiologic diagnosis is often missing, and clinical assessment of severity is difficult. Few studies have described (SSTIs) in patients with so
Externí odkaz:
https://doaj.org/article/c8253c16b6a342debc7e4ab5ddd47f4a
Autor:
Kostas Kalbakis, Dora Hatzidaki, Vassilis Georgoulias, Nikolaos Vardakis, Aris Polyzos, Nikolaos Kentepozidis, Athanasios Kotsakis, John Syrios, Charalambos Kouroussis, Emmanouil Kontopodis
Publikováno v:
Minerva ginecologica. 71(3)
Background Evaluation of safety of the weekly intravenous gemcitabine/topotecan combination as salvage treatment in patients with recurrent epithelial ovarian cancer. Methods Twenty-four women with histologically-proven relapsed ovarian cancer (ROC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64e67dcddfcf87a424099cc6c438df32
https://pubmed.ncbi.nlm.nih.gov/30727721
https://pubmed.ncbi.nlm.nih.gov/30727721
Autor:
Nikolaos Kentepozidis, Nikolaos Ziras, Nikolaos A. Malamos, Dimitrios Mavroudis, Stylianos Kakolyris, Vassilis Georgoulias, P. Papakotoulas, Elias Athanasiadis, Kostas Kalbakis, Charalambos Christophyllakis, Ioannis Boukovinas
Publikováno v:
Cancer Research. 75:P3-09
Background: The dose dense sequential administration of anthracycline and taxane is very effective as adjuvant therapy in node-positive early breast cancer. The non-anthracycline regimen docetaxel plus cyclophosphamide (TC regimen) was better than fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::866a9200eccdbf32d4b9040f48fd3d9a
https://doi.org/10.1158/1538-7445.sabcs14-p3-09-01
https://doi.org/10.1158/1538-7445.sabcs14-p3-09-01
Autor:
P. Economopoulou, Athanasios Kotsakis, Kostas Kalbakis, Leonidas Chelis, Lambros Vamvakas, N. Vardakis, F. Koinis, Ch. Nikolaou, Aris Polyzos, V. Georgoulias, Nikolaos Kentepozidis, P. Katsaounis, Ch. Christofyllakis
Publikováno v:
Clinical and Translational Oncology. 19:317-325
Platinum-based chemotherapy is the standard front-line treatment for patients with advanced non-small cell lung cancer (NSCLC). However, non-platinum combinations of third-generation chemotherapeutic agents are considered an alternative therapeutic o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dc3a04e15dacd7b5a919ad3480aff29
https://doi.org/10.1007/s12094-016-1532-y
https://doi.org/10.1007/s12094-016-1532-y
Autor:
Emmanouil Saloustros, P. Papakotoulas, C. Christophylakis, Eleni Timotheadou, Kostas Kalbakis, V. Georgoulias, G. Rigas, Sophia Agelaki, I-I Varthalitis, I. Boukovinas, S. Kakolyris, Nikolaos K. Kentepozidis, Nikolaos Ziras, D. Mavroudis
Publikováno v:
Cancer Research. 76:P1-12
Purpose: To compare the sequential versus the concurrent administration of epirubicin and docetaxel as adjuvant therapy in high risk axillary node negative women with early breast cancer. Patients and treatment: Women 18-75 years old with invasive br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6147beb245d57cf8980153a61aaf699a
https://doi.org/10.1158/1538-7445.sabcs15-p1-12-02
https://doi.org/10.1158/1538-7445.sabcs15-p1-12-02